Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Lambert, Nicolas; Dauby, Solène; DIVE, Dominique; SADZOT, Bernard; MAQUET, Pierre

doi:10.3201/eid2801.204809

Download

Article (Scientific journals)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Lambert, Nicolas; Dauby, Solène; DIVE, Dominique et al.

2022 • In Emerging Infectious Diseases, 28 (1)

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/265782

DOI
10.3201/eid2801.204809

PubMed
34856110

Files (4)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Manuscript Atezolizumab for PML Clean.docx

Author preprint (31.13 kB)

Download

Annexes

Figure.pdf

Publisher postprint (515.49 kB)

Figure

Request a copy

Appendix 1 .pdf

Publisher postprint (2.81 MB)

Appendix 1

Request a copy

Appendix 2.pdf

Publisher postprint (603.55 kB)

Appendix 2

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

atzolizumab; progressive multifocal leukoencephalopathy; Jc virus

Abstract :

[en] Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in immune reconstitution inflammatory syndrome and life-threatening immune-related adverse events. These conditions were treated with corticosteroids, leading to treatment resistance.

Disciplines :

Immunology & infectious disease
Neurology

Author, co-author :

Lambert, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

Dauby, Solène ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

DIVE, Dominique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Unité de revalidation neurologique (Esneux)

SADZOT, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

MAQUET, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

Language :

English

Title :

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Publication date :

January 2022

Journal title :

Emerging Infectious Diseases

ISSN :

1080-6040

eISSN :

1080-6059

Publisher :

U.S. National Center for Infectious Diseases, United States - Georgia

Volume :

Issue :

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 06 December 2021

Statistics

Number of views

185 (9 by ULiège)

Number of downloads

42 (9 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021; 17:37-51. https://doi.org/10.1038/s41582-020-00427-y
Beck ES, Cortese I. Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy. Curr Opin Virol. 2020; 40:19-27. https://doi.org/10.1016/j.coviro.2020.02.005
Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013; 80:1430-8. https://doi.org/10.1212/WNL.0b013e31828c2fa1
Antoniol C, Jilek S, Schluep M, Mercier N, Canales M, Le Goff G, et al. Impairment of JCV-specific T-cell response by corticotherapy: Effect on PML-IRIS management? Neurology. 2012; 79:2258-64. https://doi.org/10.1212/WNL.0b013e3182768983
Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S, et al. Selective inhibition of lowaffinity memory CD8+ T cells by corticosteroids. J Exp Med. 2019; 216:2701-13. https://doi.org/10.1084/jem.20190738
Tan CS, Bord E, Broge TA Jr, Glotzbecker B, Mills H, Gheuens S, et al. Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy. J Acquir Immune Defic Syndr. 2012; 60:244-8. https://doi.org/10.1097/QAI.0b013e31825a313c
Audemard-Verger A, Gasnault J, Faisant M, Besse MC, Martin-Silva N, Berra M, et al. Sustained response and rationale of programmed cell death-1-targeting for progressive multifocal leukoencephalopathy. Open Forum Infect Dis. 2019; 6:ofz374. https://doi.org/10.1093/ofid/ofz374
Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 2010; 3:81-91. https://doi.org/10.1038/mi.2009.112
Kon E, Benhar I. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. Drug Resist Updat. 2019; 45:13-29. https://doi.org/10.1016/j.drup.2019.07.004
Medrano C, Vergez F, Mengelle C, Faguer S, Kamar N, Del Bello A. Effectiveness of immune checkpoint inhibitors in transplant recipients with progressive multifocal leukoencephalopathy. Emerg Infect Dis. 2019; 25:2145-7. https://doi.org/10.3201/eid2511.190705